Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | CD4 | P01730 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25238614 | 0.82 | NOTUM (0.42) | CYP2D6ALDH1A1LMNAGAACYP3A4 | |
| SCHEMBL26969713 | 0.81 | TACR1 (0.43) | GAA | |
| SCHEMBL26969782 | 0.81 | NOTUM (0.41) | CYP2D6ALDH1A1LMNAGAACYP3A4 | |
| SCHEMBL25234751 | 0.80 | MEN1 (0.38) | TSHRMEN1LMNAL3MBTL1KDM4E | |
| SCHEMBL26969745 | 0.79 | HDAC1 (0.41) | TSHR | |
| SCHEMBL25279584 | 0.79 | ACLY (0.53) | CYP2D6TSHRLMNAGAACYP3A4 | |
| SCHEMBL25231173 | 0.79 | NPY5R (0.38) | ALDH1A1 | |
| SCHEMBL26969766 | 0.79 | NPY5R (0.38) | ALDH1A1GAA | |
| SCHEMBL25232157 | 0.78 | NPY5R (0.41) | MEN1KMT2ALMNAL3MBTL1KDM4E | |
| SCHEMBL26969707 | 0.78 | TSHR (0.38) | CYP2D6TSHRALDH1A1GAACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | CXCR4 2990/4885CYP2D6 2369/4885USP2 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.